Article written

  • on 18.11.2014
  • at 12:00 AM
  • by admin

Elekta’s Clarity Soft Tissue Visualization System Cleared for Use for Cancer Patients In China


By a News Reporter-Staff News Editor at China Weekly News Men with prostate cancer will be the first group of patients inChina to benefit from the recent clearance of Elekta’s (EKTA-B.ST) Clarity? soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta’s premiere linear accelerator offering, Versa HD?, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.
“As radiation oncology equipment becomes increasingly available to Chinese clinicians, and as demand grows, Elekta is providing world-class solutions, such as Clarity, to meet the specific needs of this market,” saysAnming Gong, Elekta’s Managing Director forChina.
The authorization for Clarity use in China follows the CFDA’s clearance in September of Elekta’s Versa HD? linear accelerator, enabling Elekta to sell and market the system inChina.
According to the International Agency for Research on Cancer, well over three million people are diagnosed with cancer every year inChina1. Prostate cancer is the sixth most common cancer for men inChina2.
Keywords for this news article include: Asia, China, Cancer, Elekta, Oncology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
(c) 2014 NewsRx LLC

subscribe to comments RSS

Comments are closed